Array Digital Infrastructure, Inc. (AD)

NYQ – Цена в реальном времени. Валюта: USD

37.07

+1.18 (3.29%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

37.07

0.00 (0.00%)

После закрытия: Jun 26, 2026, 5:05 PM EDT

17.06.2026

Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer's Patients

BRONX, N.Y.--(BUSINESS WIRE)-- #Alzheimers--Oligomerix, Inc., a privately held clinical stage company pioneering the development of oral, small molecule therapeutics targeting Alzheimer's (AD) and rare neurodegenerative diseases, announced an NIH Fast Track Phase II award of $1.9 million from the National Institute on Aging of the National Institutes of Health. This grant supports clinical development of OLX-07010, an orally administered investigational drug, targeting pathological tau aggregates that drive.

11.06.2026

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

CAMBRIDGE, Mass. and TAIPEI, June 10, 2026 /PRNewswire/ -- Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmune diseases, today announced positive interim results from its ongoing Phase 2 proof-of-concept study of enrupatinib (EI-1071), a brain-penetrant colony-stimulating factor 1 receptor (CSF-1R) inhibitor designed to modulate neuroinflammation in Alzheimer's disease (AD).

01.06.2026

Array completes sale of select spectrum assets to Verizon for $1.0 billion

Board declares special dividend of $11.00 per share CHICAGO, June 1, 2026 /PRNewswire/ -- Array Digital Infrastructure, Inc. (NYSE: AD) (ArraySM) today announced the successful closing of the previously announced agreement with Verizon (NYSE: VZ) to sell a portion of the Company's retained spectrum licenses for total consideration of $1.0 billion. Additionally, certain spectrum sales to T-Mobile totaling $168M, primarily related to 700MHz and 600MHz, were completed in May.

19.05.2026

Array Digital Infrastructure, Inc. (AD) Shareholder/Analyst Call Prepared Remarks Transcript

15.05.2026

ARRAY DIGITAL STOCK ALERT: Kaskela Law Firm Announces Stockholder Investigation of Array Digital Infrastructure, Inc. (AD) and Encourages Investors with Losses to Contact the Firm - PLTK

PHILADELPHIA, May 15, 2026 /PRNewswire/ -- Stockholder litigation firm Kaskela Law announces that it is investigating Array Digital Infrastructure, Inc. (NYSE: AD) ("Array") on behalf of the company's investors. Click here for additional information: https://kaskelalaw.com/case/array-digital/ The investigation seeks to determine whether Array and/or the company's officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.

14.05.2026

AD Long-Term Investors Have the Opportunity to Join Investigation of Array Digital Infrastructure, Inc. with the Schall Law Firm

LOS ANGELES, May 14, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of long-term investors in Array Digital Infrastructure, Inc. (“Array Digital” or “the Company”) (NYSE: AD) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Array Digital board breached its fiduciary duties to shareholders, and if the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

12.05.2026

STOCKHOLDER NOTIFICATION: Kaskela Law is Investigating Array Digital Infrastructure, Inc. (AD) and Encourages Long-Term Investors to Contact the Firm

The firm is investigating whether the company's representatives violated the securities laws or breached their fiduciary duties, causing investor losses Array's stock price has declined over 21% since August 2025 PHILADELPHIA, May 12, 2026 (GLOBE NEWSWIRE) -- Kaskela Law is investigating Array Digital Infrastructure, Inc. (NYSE: AD) (“Array”) on behalf of the company's long-term shareholders. Click here for additional information: https://kaskelalaw.com/case/array-digital/ Since August 2025, shares of Array's common stock have declined in value from a trading price of over $70.00 per share to a current price of approximately $55.00 per share – a cumulative decline of over 21% in value.

Видео

No Data

There is no data to display

Пресс-релизы

17.06.2026

Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer's Patients

11.06.2026

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

01.06.2026

Array completes sale of select spectrum assets to Verizon for $1.0 billion

15.05.2026

ARRAY DIGITAL STOCK ALERT: Kaskela Law Firm Announces Stockholder Investigation of Array Digital Infrastructure, Inc. (AD) and Encourages Investors with Losses to Contact the Firm - PLTK

Array Digital Infrastructure, Inc. (AD)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Array Digital Infrastructure, Inc. (AD)

Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer's Patients

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

Array completes sale of select spectrum assets to Verizon for $1.0 billion

Array Digital Infrastructure, Inc. (AD) Shareholder/Analyst Call Prepared Remarks Transcript

ARRAY DIGITAL STOCK ALERT: Kaskela Law Firm Announces Stockholder Investigation of Array Digital Infrastructure, Inc. (AD) and Encourages Investors with Losses to Contact the Firm - PLTK

AD Long-Term Investors Have the Opportunity to Join Investigation of Array Digital Infrastructure, Inc. with the Schall Law Firm

STOCKHOLDER NOTIFICATION: Kaskela Law is Investigating Array Digital Infrastructure, Inc. (AD) and Encourages Long-Term Investors to Contact the Firm

Видео

No Data

Пресс-релизы

Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer's Patients

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

Array completes sale of select spectrum assets to Verizon for $1.0 billion

ARRAY DIGITAL STOCK ALERT: Kaskela Law Firm Announces Stockholder Investigation of Array Digital Infrastructure, Inc. (AD) and Encourages Investors with Losses to Contact the Firm - PLTK

Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer's Patients

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

Array completes sale of select spectrum assets to Verizon for $1.0 billion

Array Digital Infrastructure, Inc. (AD) Shareholder/Analyst Call Prepared Remarks Transcript

ARRAY DIGITAL STOCK ALERT: Kaskela Law Firm Announces Stockholder Investigation of Array Digital Infrastructure, Inc. (AD) and Encourages Investors with Losses to Contact the Firm - PLTK

AD Long-Term Investors Have the Opportunity to Join Investigation of Array Digital Infrastructure, Inc. with the Schall Law Firm

STOCKHOLDER NOTIFICATION: Kaskela Law is Investigating Array Digital Infrastructure, Inc. (AD) and Encourages Long-Term Investors to Contact the Firm

Видео

No Data

Пресс-релизы

Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer's Patients

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

Array completes sale of select spectrum assets to Verizon for $1.0 billion

ARRAY DIGITAL STOCK ALERT: Kaskela Law Firm Announces Stockholder Investigation of Array Digital Infrastructure, Inc. (AD) and Encourages Investors with Losses to Contact the Firm - PLTK

Search stocks

Array Digital Infrastructure, Inc. (AD)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Array Digital Infrastructure, Inc. (AD)

Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer's Patients

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

Array completes sale of select spectrum assets to Verizon for $1.0 billion

Array Digital Infrastructure, Inc. (AD) Shareholder/Analyst Call Prepared Remarks Transcript

ARRAY DIGITAL STOCK ALERT: Kaskela Law Firm Announces Stockholder Investigation of Array Digital Infrastructure, Inc. (AD) and Encourages Investors with Losses to Contact the Firm - PLTK

AD Long-Term Investors Have the Opportunity to Join Investigation of Array Digital Infrastructure, Inc. with the Schall Law Firm

STOCKHOLDER NOTIFICATION: Kaskela Law is Investigating Array Digital Infrastructure, Inc. (AD) and Encourages Long-Term Investors to Contact the Firm

Видео

No Data

Пресс-релизы

Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer's Patients

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

Array completes sale of select spectrum assets to Verizon for $1.0 billion

ARRAY DIGITAL STOCK ALERT: Kaskela Law Firm Announces Stockholder Investigation of Array Digital Infrastructure, Inc. (AD) and Encourages Investors with Losses to Contact the Firm - PLTK

Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer's Patients

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

Array completes sale of select spectrum assets to Verizon for $1.0 billion

Array Digital Infrastructure, Inc. (AD) Shareholder/Analyst Call Prepared Remarks Transcript

ARRAY DIGITAL STOCK ALERT: Kaskela Law Firm Announces Stockholder Investigation of Array Digital Infrastructure, Inc. (AD) and Encourages Investors with Losses to Contact the Firm - PLTK

AD Long-Term Investors Have the Opportunity to Join Investigation of Array Digital Infrastructure, Inc. with the Schall Law Firm

STOCKHOLDER NOTIFICATION: Kaskela Law is Investigating Array Digital Infrastructure, Inc. (AD) and Encourages Long-Term Investors to Contact the Firm

Видео

No Data

Пресс-релизы

Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer's Patients

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

Array completes sale of select spectrum assets to Verizon for $1.0 billion

ARRAY DIGITAL STOCK ALERT: Kaskela Law Firm Announces Stockholder Investigation of Array Digital Infrastructure, Inc. (AD) and Encourages Investors with Losses to Contact the Firm - PLTK